Evidence map›Paper›PMID 40240504›Full record

Trial reportScientific reports2025

Transmissibility of a new Plasmodium falciparum 3D7 bank for use in malaria volunteer infection studies evaluating transmission blocking interventions.

Sean A Lynch, Azrin N Abd-Rahman, Jenny M Peters, Juanita M Heunis, Jeremy S E Gower, Adam J Potter, Rebecca Webster, Helen Jennings, Susan Mathison, Nischal Sahai and 2 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sean A LynchQIMR Berghofer, 300 Herston Rd, Herston, Brisbane, QLD, 4006, Australia.
Azrin N Abd-RahmanQIMR Berghofer, 300 Herston Rd, Herston, Brisbane, QLD, 4006, Australia.
Jenny M PetersQIMR Berghofer, 300 Herston Rd, Herston, Brisbane, QLD, 4006, Australia.
Juanita M HeunisQIMR Berghofer, 300 Herston Rd, Herston, Brisbane, QLD, 4006, Australia.
Jeremy S E GowerQIMR Berghofer, 300 Herston Rd, Herston, Brisbane, QLD, 4006, Australia.
Adam J PotterQIMR Berghofer, 300 Herston Rd, Herston, Brisbane, QLD, 4006, Australia.
Rebecca WebsterQIMR Berghofer, 300 Herston Rd, Herston, Brisbane, QLD, 4006, Australia.
Helen JenningsQIMR Berghofer, 300 Herston Rd, Herston, Brisbane, QLD, 4006, Australia.
Susan MathisonUniversity of the Sunshine Coast Clinical Trials, Brisbane, QLD, Australia.
Nischal SahaiUniversity of the Sunshine Coast Clinical Trials, Brisbane, QLD, Australia.
Fiona H AmanteQIMR Berghofer, 300 Herston Rd, Herston, Brisbane, QLD, 4006, Australia.
Bridget E BarberQIMR Berghofer, 300 Herston Rd, Herston, Brisbane, QLD, 4006, Australia. bridget.barber@qimrb.edu.au.

Funding

Australian National Health and Medical Research Council Investigator Grant #2016792
6 · The paper itself

Abstract

Transmission blocking activity is an important characteristic of antimalarial drugs, and can be evaluated in malaria volunteer infection studies (VIS). We undertook a pilot VIS to evaluate the suitability of a recently manufactured Plasmodium falciparum 3D7 bank (3D7-MBE-008) for evaluating transmission blocking interventions. Four adults were inoculated with P. falciparum 3D7-MBE-008 infected erythrocytes and administered piperaquine on days 8 and 10 to clear asexual parasitemia while permitting gametocyte development. On day 25, participants were randomised (1:1) to receive either 0.25 mg/kg primaquine (primaquine group) or no intervention (control group). Transmissibility was assessed by enriched membrane feeding assays on days 25, 29, 32, and 39, with transmission intensity (proportion of mosquitoes infected) determined by 18S qPCR. All participants were infective on day 25, with a median 94% (range, 12-100%) of mosquitoes positive for oocysts, and 76% (range, 8-94%) positive for sporozoites. In the primaquine group, mosquito infectivity decreased substantially between days 25 and 29. In the control group, mosquito infectivity remained high up to day 32, and persisted to day 39 in one participant. The P. falciparum 3D7-MBE-008 parasite bank induced blood-stage infections that were highly transmissible to mosquitoes and is therefore suitable for evaluating transmission blocking interventions.Trial registration anzctr.org.au (registration number: ACTRN12622001097730), registered 08/08/2022.

Indexed as

AntimalarialsMalaria, FalciparumPlasmodium falciparumAdultAnimalsErythrocytesFemaleHumansMaleParasitemiaPiperazinesPrimaquineQuinolinesAntimalarialspiperaquinePiperazinesPrimaquineQuinolinesAnophelesClinical trialControlled human malaria infectionGametocyteMalaria transmissionOocysts

Identifiers

PMID40240504
PMCPMC12003780

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.